Elagolix N-oxide impurity

Elagolix N-oxide impurity is an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone receptor antagonist. It is used in the treatment of reproductive hormone-related disorders such as endometriosis and leiomyoma. It reduces ovarian sex hormones in the blood.

Additional information

Catalogue No.

VE006851

CAS No.

N/A

Molecular Formula

C32H29F5N3NaO6

Molecular Weight

669.57

IUPAC Name

Sodium (R)-4-((2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2, 6-dioxo-3, 6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl)(hydroxy)amino)butanoate

References

Lamb, Yvette N. “Elagolix: First Global Approval.” Drugs, vol. 78, no. 14, Sept. 2018, pp. 1501–8, https://doi.org/10.1007/s40265-018-0977-4. Carr, Bruce, et al. “Elagolix, an Oral GnRH Antagonist, versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis.” Reproductive Sciences, vol. 21, no. 11, Sept. 2014, pp. 1341–51, https://doi.org/10.1177/1933719114549848.

Status

In-stock